Generisches Avandamet ist eine Kombination aus zwei, oralen Medikamenten, um den Blutzuckerspiegel zu kontrollieren. Es ist speziell für PatientInnen, die Diabetes des Typ 2 haben und nicht täglich Insulin brauchen.
Generisches Avandaryl ist eine Kombination aus zwei Diabetes-Medikamenten, um den Blutzucker zu kontrollieren und wirkt bei Diabetes Typ2 (keine tägliche Insulininjektion).
Metformin And Rosiglitazone Combo Best For Kids With Diabetes Type 2 - Medical News Today
CBS NewsMetformin And Rosiglitazone Combo Best For Kids With Diabetes Type 2Medical News TodayControlling blood sugar in children and teenagers with diabetes type two is best achieved with a metformin plus rosiglitazone combo, compared to just metformin or metformin plus lifestyle changes, researchers reported in NEJM (New England Journal of .
Effective New Treatment For Type 2 Diabetes In Youth - Daily Gossip
Daily GossipEffective New Treatment For Type 2 Diabetes In YouthDaily GossipThe study has shown that the combination of metformin and rosiglitazone is much more effective than metformin alone.
Study Says Best Drug Combo for Type 2 Kids Is Metformin and Rosiglitazone - Diabetes Health (press release)
Study Says Best Drug Combo for Type 2 Kids Is Metformin and RosiglitazoneDiabetes Health (press release)A university study has concluded that a combination of metformin and rosiglitazone (Avandia) is the best drug therapy for controlling blood sugar levels in type 2 children and adolescents.
Double-drug diabetes treatment disappoints in kids - Chicago Tribune
CBS NewsDouble-drug diabetes treatment disappoints in kidsChicago TribuneWithin a year, on average, half of kids on metformin and some 40 percent taking both metformin and rosiglitazone (Avandia) ended up having to resort to insulin injections to control their blood sugar, researchers reported Sunday at the annual meeting .
Glitazones Take New Hit for Bladder Ca Risk - MedPage Today
Glitazones Take New Hit for Bladder Ca RiskMedPage TodayNote that the analysis indicated that pioglitazone (Actos) posed no more risk than rosiglitazone (Avandia) with respect to risk of bladder cancer.